Top Page
Legend Biotech
(NASDAQ:LEGN)
Legend Biotech (LEGN) vs. SPDR S&P 500 ETF (SPY)
Legend Biotech Business Overview & Revenue Model
Legend Biotech Key Performance Indicators (KPIs)
Reflects the sales performance of Carvykti, a key product, indicating its market acceptance and contribution to the company’s revenue growth.
The FlyLegend Biotech Earnings Call Summary
Legend Biotech Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 908.96M | 627.24M | 285.14M | 117.00M | 68.83M | 75.00M |
| Gross Profit | 550.40M | 392.66M | 140.93M | 51.64M | 68.83M | 75.00M |
| EBITDA | -183.33M | -113.16M | -477.87M | -416.54M | -392.38M | -298.16M |
| Net Income | -239.70M | -177.03M | -518.25M | -446.35M | -403.58M | -266.37M |
Balance Sheet | ||||||
| Total Assets | 1.71B | 1.67B | 1.85B | 1.33B | 1.12B | 722.09M |
| Cash, Cash Equivalents and Short-Term Investments | 992.59M | 1.12B | 1.31B | 1.03B | 882.39M | 506.07M |
| Total Debt | 410.24M | 350.60M | 328.67M | 284.53M | 122.97M | 3.70M |
| Total Liabilities | 701.69M | 629.61M | 597.24M | 586.65M | 353.52M | 122.27M |
| Stockholders Equity | 1.01B | 1.04B | 1.25B | 744.31M | 765.94M | 597.77M |
Cash Flow | ||||||
| Free Cash Flow | -188.68M | -158.14M | -416.00M | -223.56M | -243.87M | -253.29M |
| Operating Cash Flow | -170.07M | -144.03M | -393.28M | -201.28M | -198.47M | -223.00M |
| Investing Cash Flow | -16.73M | -850.54M | 92.79M | -77.09M | -194.98M | -24.17M |
| Financing Cash Flow | 14.00K | 5.70M | 791.49M | 377.98M | 626.66M | 618.88M |
Legend Biotech Technical Analysis
Legend Biotech Risk Analysis
Legend Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $10.91B | -17.31 | -32.44% | ― | 106.27% | -43.90% | |
60 Neutral | $9.18B | -45.87 | ― | ― | ― | 18.47% | |
59 Neutral | $7.48B | -36.38 | -240.36% | ― | 54.92% | 28.47% | |
57 Neutral | $7.67B | -10.40 | ― | ― | 2609.26% | -17.08% | |
57 Neutral | $7.70B | -33.10 | -275.50% | ― | 65.83% | 28.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $4.05B | -17.37 | -22.60% | ― | 74.91% | 31.54% |
Legend Biotech Corporate Events
On December 6, 2025, Legend Biotech announced new data from the CARTITUDE studies at the ASH Annual Meeting, highlighting the long-term benefits of CARVYKTI® in treating relapsed/refractory multiple myeloma. The studies showed significant progression-free survival benefits, especially when used earlier in treatment. Additionally, first-in-human results for LUCAR-G39D in non-Hodgkin lymphoma demonstrated promising safety and efficacy. These findings reinforce Legend Biotech’s position in the cell therapy market and suggest potential improvements in patient outcomes.
On November 12, 2025, Legend Biotech reported its unaudited financial results for the third quarter of 2025, highlighting significant growth in CARVYKTI® sales, with net trade sales reaching approximately $524 million. The company also announced regulatory updates, including FDA and European Commission label updates for CARVYKTI® to reflect its overall survival benefit. Legend Biotech has treated over 9,000 patients to date and initiated commercial production at its Tech Lane facility in Belgium. Financially, the company reported a net loss of $39.7 million for the quarter, a significant improvement from the $125.3 million loss in the same period of 2024. The company holds approximately $1.0 billion in cash and equivalents, providing a financial runway beyond 2026, with expectations of achieving company-wide profitability in 2026.
On November 3, 2025, Legend Biotech announced its participation in the 67th American Society of Hematology Annual Meeting, where it will present research on CARVYKTI® and a novel therapy, Lucar-G39D. These presentations highlight the company’s ongoing innovation in cell therapy and its efforts to expand treatment options for multiple myeloma and B-cell non-Hodgkin lymphoma, potentially impacting clinical practices and patient outcomes.
On October 10, 2025, Legend Biotech announced that the U.S. FDA approved a label update for its CARVYKTI® CAR-T cell therapy to include overall survival data from the Phase 3 CARTITUDE-4 study. This update highlights a significant improvement in overall survival for patients with relapsed, refractory multiple myeloma compared to standard care. Additionally, the label now includes warnings about immune effector cell-associated enterocolitis and the reactivation of the John Cunningham virus, which can lead to serious complications, emphasizing the need for careful management by prescribing physicians.
On October 14, 2025, Legend Biotech announced that its product CARVYKTI® achieved approximately $524 million in net trade sales for the quarter ending September 30, 2025. This announcement highlights the product’s significant market performance, although the sales figures are preliminary and subject to further financial review. The impact on Legend Biotech’s operations and industry positioning is notable, as it underscores the company’s growing influence in the biotechnology sector.
On October 6, 2025, Legend Biotech USA Inc., a subsidiary of Legend Biotech Corporation, entered into a Component and Product Supply Agreement with Janssen Pharmaceuticals, Inc. This agreement, which supersedes a previous interim agreement from February 2022, involves the manufacturing and supply of ciltacabtagene autoleucel (cilta-cel) for clinical and commercial use globally, excluding Greater China. The agreement outlines the shared costs and responsibilities between Legend Biotech and Janssen, including the supply of raw materials and the handling of production costs. This strategic partnership is expected to enhance Legend Biotech’s operational capabilities and strengthen its position in the global biotechnology market.